60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM)(SXTPW.US)

Company Encyclopedia
View More
name
60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM)
SXTPW.US
News
View More

Muna Therapeutics receives $1 million grant for Alzheimer's drug development, advancing Phase 1 trial of MNA-001.

Financial support has been secured for the continuation of the Phase 1 trial of MNA-001 and the validation of translational biomarkers related to TREM2 function in Alzheimer's disease. This funding will aid in conducting Phase 2 trials to evaluate the ability of MNA-001 to decelerate the progression of pathology and functional decline in patients. The validation of these translational biomarkers serves to validate Muna's distinctive approach in this research.

Unusual Whales·
Unusual Whales·

Genomic Biomarkers Market to reach $50.31 billion by 2030, growing at a CAGR of 11.6% from $29.00 billion in 2025.

A recent report from MarketsandMarkets™ reveals that the Genomic Biomarkers Market is expected to witness significant growth, with projections indicating an increase from approximately USD 29.00 billion in 2025 to USD 50.31 billion by 2030. This growth reflects a Compound Annual Growth Rate (CAGR) of 11.6%. The report includes comprehensive market data, consisting of 708 tables and 56 figures distributed across 506 pages.

Unusual Whales·
Unusual Whales·

Epistemic AI Analysis Reveals Strategic Business Decisions as the Leading Driver of Phase 3 Clinical Trial Terminations

A study by Epistemic AI published in Nature Reviews Drug Discovery reveals that strategic business decisions are the leading cause of Phase 3 clinical trial terminations, with rates doubling from 11% to 22% over the last decade. The research highlights a shift in pharmaceutical decision-making, where business factors like M&A activity now surpass clinical efficacy as reasons for trial failures. The study aims to inform decision-making to accelerate patient treatments and optimize drug development resources.

biopharmadive·
biopharmadive·

Psoriasis market to grow at 1.7% CAGR from 2025-2034 due to biologic innovations. Transition to high-efficacy treatments noted.

The market for psoriasis is steadily growing due to an increase in the number of people suffering from the disease, better detection rates, and increased patient availability of advanced treatments. There has been a notable transition from traditional systemic treatments to more effective biologics and targeted oral medications. This shift has led to a significant increase in revenue, with the market now valued at approximately [provide exact number if available].

Unusual Whales·
Unusual Whales·

Surfing the AI wave: How pharma can harness agents in ERP

The rapid adoption of AI technology is transforming the pharmaceutical industry, enabling companies to streamline operations and enhance productivity. AI can alleviate repetitive tasks, allowing teams to focus on strategic initiatives. The journey of AI adoption unfolds in three phases: 1) Assistants that boost personal productivity, 2) Agents that automate structured processes, and 3) Autonomous processes that manage entire workflows. Successful implementation requires a focus on enriching employee experience, reinventing external engagement, reshaping business processes, and accelerating innovation. Companies must choose the right use cases to maximize AI's potential.

biopharmadive·
biopharmadive·
© 2026 Longbridge｜Disclaimer